Retinalamin

Retinalamin – the ophthalmologic drug promoting improvement of a functional condition of a retina.

Form of release and structure

Dosage form of release of Retinalamin – lyophilisate for preparation of solution for intramuscular and parabulbar introduction: either the white porous weight or powder, white with a yellowish shade (on 5 bottles in blister strip packagings, in a cardboard pack 2 packagings).

With lyophilisate is a part of 1 bottle:

• Active agent: polypeptide water-soluble fractions of a retina of an eye of the cattle (complex) – 5 mg;
• Additional component (as the stabilizer): glycine – 17 mg.

Indications to use

• Miopichesky disease (in combination with other drugs);
• Diabetic retinopathy;
• Primary open angle glaucoma (compensated);
• The central degeneration of a retina, including diseases of an inflammatory and traumatic etiology;
• Tapetoretinalny abiotrophy (central and peripheral).

Contraindications

• Pregnancy and the period of feeding (the safety profile for this group of patients is not studied);
• Age till 1 year (a tapetoretinalny abiotrophy (central and peripheral), the central dystrophy of a retina of an inflammatory and traumatic etiology) and up to 18 years (the compensated primary open angle glaucoma, a diabetic retinopathy, a miopichesky disease – the safety profile for this age group of patients is not studied);
• Hypersensitivity to drug components.

Route of administration and dosage

The recommended scheme of use of Retinalamin for adults:

• Diabetic retinopathy, central dystrophy of a retina of a traumatic and inflammatory etiology, central and peripheral tapetoretinalny abiotrophy: once a day on 5-10 mg intramusculary or parabulbarno, course duration – 5-10 days, in 3-6 months therapy repetition is possible;
• The compensated primary open angle glaucoma: once a day on 5 mg intramusculary or parabulbarno, course duration – 10 days, in 3-6 months therapy repetition is possible;
• Miopichesky disease: once a day on 5 mg parabulbarno, course duration – 10 days; it is recommended to carry out therapy in combination with vitamins of group B and angioprotektorny means.

Before introduction drug is dissolved in water for injections, by 0,9% solution of sodium chloride or 0,5% solution of novocaine (Procainum) of 1-2 ml. To avoid foaming, the needle needs to be directed to a bottle wall.

The recommended scheme of use of Retinalamin for children at treatment of the central dystrophy of a retina of an inflammatory and traumatic etiology, peripheral and central tapetoretinalny abiotrophy (parabulbarno or intramusculary with frequency rate of introduction once a day):

• 1-5 years – 2,5 mg;
• 6-18 years – 2,5-5 mg.

Previously Retinalamin it is necessary to part in 0,9% solution of sodium chloride of 1-2 ml. To avoid foaming, the needle needs to be directed to a bottle wall.

Course duration – 10 days, in 3-6 months therapy repetition is possible.

Side effects

Data on development of side effects are absent.

With individual hypersensitivity to the components which are a part of drug development of allergic reactions can be observed.

Special instructions

Features of action of Retinalamin at the first use and after its cancellation are absent.

Drug needs to be used only on medical appointment.

After dissolution Retinalamin it is necessary to use at once.

At the admission of an injection it is not necessary to enter the doubled dose, the following injection is entered in the planned day (according to the standard scheme).

Retinalamin with other solutions is not recommended to mix.

Medicinal interaction

Data on significant interaction of Retinalamin with other substances / drugs in the instruction are absent.

Terms and storage conditions

To store in protected from light, the place, unavailable to children, at a temperature of 2-20 °C.

Period of validity – 3 years.